Tandem Investment Advisors Inc. Has $48.73 Million Stake in Johnson & Johnson (NYSE:JNJ)

Tandem Investment Advisors Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 41.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 293,806 shares of the company's stock after selling 207,069 shares during the period. Johnson & Johnson comprises 1.7% of Tandem Investment Advisors Inc.'s holdings, making the stock its 28th largest holding. Tandem Investment Advisors Inc.'s holdings in Johnson & Johnson were worth $48,725,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. ZWJ Investment Counsel Inc. raised its stake in shares of Johnson & Johnson by 1.4% during the first quarter. ZWJ Investment Counsel Inc. now owns 211,708 shares of the company's stock valued at $35,110,000 after acquiring an additional 2,851 shares during the last quarter. Clark Asset Management LLC grew its stake in shares of Johnson & Johnson by 5.6% in the first quarter. Clark Asset Management LLC now owns 5,859 shares of the company's stock worth $972,000 after purchasing an additional 310 shares during the last quarter. Smart Money Group LLC raised its position in Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company's stock worth $1,109,000 after purchasing an additional 407 shares during the last quarter. Resonant Capital Advisors LLC lifted its holdings in Johnson & Johnson by 9.0% during the 1st quarter. Resonant Capital Advisors LLC now owns 28,653 shares of the company's stock worth $4,752,000 after buying an additional 2,366 shares during the period. Finally, Global Strategic Investment Solutions LLC grew its position in shares of Johnson & Johnson by 6.3% in the 1st quarter. Global Strategic Investment Solutions LLC now owns 1,860 shares of the company's stock valued at $308,000 after buying an additional 111 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on JNJ. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

Shares of JNJ traded up $0.34 during mid-day trading on Friday, reaching $155.90. The company had a trading volume of 3,482,521 shares, compared to its average volume of 8,047,072. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market capitalization of $375.11 billion, a P/E ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company's 50-day moving average is $153.68 and its 200-day moving average is $154.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.